Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia

American Journal of Cardiology

Volumn 80, Issue 5, 1997, Pages 608-613

  Athyros, Vasilios G ^a,b   Papageorgiou, Athanasios A ^a   Hatzikonstandinou, Haris A ^a   Didangelos, Triandafillos P ^a   Carina, Maria V ^a   Kranitsas, Dimitrios F ^a   Kontopoulos, Athanasios G ^a  

^a Aristotle University of Thessaloniki   (Greece)

^b NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CIPROFIBRATE; CREATINE KINASE; FIBRINOGEN; GEMFIBROZIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FAMILIAL HYPERLIPEMIA; FEMALE; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; HEART INFARCTION; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MYALGIA; MYOPATHY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; APOLIPOPROTEINS; CHOLESTEROL, LDL; CLOFIBRIC ACID; DRUG THERAPY, COMBINATION; FEMALE; GEMFIBROZIL; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; LOVASTATIN; MALE; MIDDLE AGED; PRAVASTATIN; SIMVASTATIN; TREATMENT OUTCOME;

EID: 0030882897     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00430-X     Document Type: Article

References (30)

1. de Oya M, Alvarez-Sala LA, Mata P, Alonzo R. The role of cholesterol in the pathogenesis of atherosclerosis. Primary and secondary causes of hyperlipidemia. In: Diez J, Dzau VJ, Ferrari R, Frohlich ED, eds. Molecular Cell Biology of Cardiovascular Diseases. Madrid: Mosby/Doyma Libros, 1995:149-179.
2. Genest JJ Jr, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J, Myers RH, Silberman SR, Wilson PW, Salem DN, Schaefer EJ. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992; 85:2025-2033.
3. Franceschini G, Cassinotti M, Vecchio G, Gianfranceschi G, Pazzucconi F, Murakami T, Sirtori M, D' Acquarica AL, Sirtori CR. Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern. Arterioscler Thromb 1994;14:1569-1575.
4. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
5. Sacks FM, Pfeffer MA, Moye LA, Rouleau JN, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
6. The Scandinavian Simvastatin Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
7. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992;85:37-45.
8. Bruckert E, Dejager S, Chapman MJ. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia. Atherosclerosis 1993;100:91-102.
9. East C, Bilheimer DW, Grundy SM. Combination drug therapy for familial combined hyperlipidemia. Ann Intern Med 1988;109:25-32.
10. Athyros V, Papageorgiou A, Hagikonstantinou H, Papadopoulos G, Zamboulis C, Kontopoulos A. Combined treatment with pravastatin and gemfibrozil in patients with refractory familial combined hyperlipidemia. Drug Invest 1994; 7:134-142.
11. Athyros V, Papageorgiou A, Avramidis M, Karayiannis A, Zamboulis C, Kontopoulos A. Effect of pravastatin on coronary heart disease prevention in patients with primary hypercholesterolemia. Curr Ther Res 1994;55:914-924.
12. Athyros V, Papageorgiou A, Avramidis M, Kontopoulos A. Long-term effect of gemfibrozil on coronary heart disease risk profile of patients with primary combined hyperlipidemia. Coron Artery Dis 1995;6:251-256.
13. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988;62:28J-34J.
14. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low density lipoprotein subclass patters and risk of myocardial infarction. JAMA 1988;260:1917-1921.
15. Tornvall P, Bavenholm P, Landou C, de Faire U, Hamsten A. Relation of plasma levels of apoprotein B-containing lipoproteins angiographically defined coronary artery disease in young patients with myocardial infarction. Circulation 1993;88:2180-2189.
16. Chait A, Brazg RL, Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993;94:350-356.
17. Heinrich J, Assmann G. Fibrinogen and cardiovascular risk. J Cardiovasc Risk 1995;2:197-205.
18. Pazzucconi F, Franceschini G, Gianfranceschi G, Brambilla E, Sirtori CR. Lipoprotein structure in male subjects during in vivo lipolysis: effect of an anti-lipolytic treatment with acipimox. J Lipid Res 1993;34:1465-1472.
19. Kehely A, MacMahon M, Barbir M, Wray R, Hunt BJ, Prescott RJ, Thompson GR. Combined bezafibrate and simvastatin treatment for mixed hyperlipidaemia. QJM 1995;88:421-427.
20. Bredie SJ, de Bruin TW, Demacker PN, Kastelein JJ, Stalenhoef AF. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. Am J Cardiol 1995;75:348-353.
21. Zambon S, Cortella A, Sartore G, Baldo Enzi G, Manzato E, Crepaldi G. Pravastatin treatment in combined hyperlipidemia. Effect on plasma lipoprotein levels and size. Eur J Clin Pharmacol 1994;46:221-224.
22. Griffin BA, Freeman DJ, Tait GW, Thompson J, Caslake MJ, Packard CJ, Shepherd J. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994;106:241-253.
23. Shepherd J. Mechanism of action of fibrates. Postgrad Med J 1993;69(suppl A):34S-41S.
24. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990;264: 71-75.
25. Kontopoulos A, Athyros V, Papageorgiou A, Hatzikonstandinou H, Mayroudi M, Boudoulas H. Effects of simvastatin and ciprofibrate alone and in combination on apolipoprotein-B-containing lipoproteins and on low density lipoprotein subfraction distribution in patients with familial combined hyperlipidemia and coronary artery disease. Coron Artery Dis 1996;7:843-850.
26. Wiklund O, Angelin B, Bergman M, Berglund L, Bondjers G, Carlsson A, Linden T, Miettinen T, Odman B, Olofsson SO, Saarinen I, Sipila R, Sjostrom P, Kron B, Vanhanen H, Wright I. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993;94: 13-20.
27. Feher MD, Foxton J, Banks D, Lant AF, Wray R. Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease. Br Heart J 1995;74:14-17.
28. Willis RA, Folkers K, Tucker JL, Ye C-Q, Xia L-J, Tamagawa H. Lovastatin decreases coenzyme Q levels in rats. Proc Natl Acad Sci USA 1990;87:8928-8930.
29. Laaksonen R, Jokelainen K, Sahi T, Tikkanen MJ, Himberg JJ. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther 1995; 57:62-66.
30. Gadbut AP, Caruso AP, Galper JB. Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin. J Mol Cell Cardiol 1995;27: 2397-2402.